EA201890859A1 - Предотвращение, лечение и обращение развития заболевания с применением терапевтически эффективных количеств активированных жирных кислот - Google Patents

Предотвращение, лечение и обращение развития заболевания с применением терапевтически эффективных количеств активированных жирных кислот

Info

Publication number
EA201890859A1
EA201890859A1 EA201890859A EA201890859A EA201890859A1 EA 201890859 A1 EA201890859 A1 EA 201890859A1 EA 201890859 A EA201890859 A EA 201890859A EA 201890859 A EA201890859 A EA 201890859A EA 201890859 A1 EA201890859 A1 EA 201890859A1
Authority
EA
Eurasian Patent Office
Prior art keywords
fatty acids
treatment
disease
prevention
development
Prior art date
Application number
EA201890859A
Other languages
English (en)
Inventor
Дайэн Йоркаски
Original Assignee
Комплекса, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Комплекса, Инк. filed Critical Комплекса, Инк.
Publication of EA201890859A1 publication Critical patent/EA201890859A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

Различные варианты реализации настоящего изобретения относятся к фармацевтическим композициям и способам лечения заболеваний, включая фокально-сегментарный гломерулосклероз или легочную артериальную гипертензию. Композиции согласно таким вариантам реализации содержат активированные жирные кислоты, такие как алкилзамещенные жирные кислоты, кетопроизводные жирных кислот и нитропроизводные жирных кислот. Способы согласно различным вариантам реализации включают введение эффективного количества 10-нитро-9(E)-октадец-9-еновой кислоты для лечения таких заболеваний.
EA201890859A 2015-10-02 2016-10-03 Предотвращение, лечение и обращение развития заболевания с применением терапевтически эффективных количеств активированных жирных кислот EA201890859A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562236702P 2015-10-02 2015-10-02
PCT/US2016/055206 WO2017059451A1 (en) 2015-10-02 2016-10-03 Prevention, treatment and reversal of disease using therapeutically effective amounts of activated fatty acids

Publications (1)

Publication Number Publication Date
EA201890859A1 true EA201890859A1 (ru) 2018-11-30

Family

ID=58428002

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201890859A EA201890859A1 (ru) 2015-10-02 2016-10-03 Предотвращение, лечение и обращение развития заболевания с применением терапевтически эффективных количеств активированных жирных кислот

Country Status (17)

Country Link
US (3) US10537541B2 (ru)
EP (1) EP3355879A4 (ru)
JP (2) JP2018529779A (ru)
KR (1) KR20180098222A (ru)
CN (2) CN108430466A (ru)
AU (2) AU2016331314A1 (ru)
BR (1) BR112018006687A2 (ru)
CA (1) CA3000842A1 (ru)
CL (1) CL2018000835A1 (ru)
CO (1) CO2018004576A2 (ru)
CR (1) CR20180246A (ru)
EA (1) EA201890859A1 (ru)
HK (1) HK1259031A1 (ru)
IL (2) IL297844A (ru)
MX (1) MX2018004043A (ru)
SG (1) SG10201913953UA (ru)
WO (1) WO2017059451A1 (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2280928T3 (en) * 2008-05-01 2018-11-05 Complexa Inc Vinyl-substituted fatty acids
US20140024713A1 (en) 2008-06-19 2014-01-23 University Of Utah Research Foundation Use of nitrated lipids for treatment of side effects of toxic medical therapies
TN2017000507A1 (en) 2015-07-07 2019-04-12 H Lundbeck As Pde9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases
CA3000842A1 (en) * 2015-10-02 2017-04-06 Complexa, Inc. Prevention, treatment and reversal of disease using therapeutically effective amounts of activated fatty acids
CN111229117B (zh) * 2018-11-29 2022-01-04 中国石油化工股份有限公司 含脂肪酸型表面活性剂的混合体系及其制备方法
CN111229120B (zh) * 2018-11-29 2022-01-07 中国石油化工股份有限公司 含脂肪酸型表面活性剂的混合体系及其制备方法
FR3092968B1 (fr) * 2019-02-22 2021-05-21 Microphyt Complement alimentaire
CN110157792A (zh) * 2019-04-22 2019-08-23 中山大学孙逸仙纪念医院 血清外泌体has_circ_0004771在制备酒精依赖综合征诊断试剂中的应用
WO2021242758A1 (en) * 2020-05-26 2021-12-02 Imara Inc. Improved nitro-fatty acid oral dose regimens
WO2023014748A1 (en) * 2021-08-03 2023-02-09 Imara Inc. Nitrated fatty acids for the treatment of sickle cell disorders

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB587992A (en) 1944-12-11 1947-05-12 Charles William Scaife Improvements in and relating to the production of organic nitrogen compounds
US3578687A (en) 1968-01-30 1971-05-11 Texaco Inc Process for producing 4-nitroalkanoic acids
US3819561A (en) 1970-10-23 1974-06-25 Aerojet General Co Wetting agents for non-aqueous dispersions
JPS5313608B2 (ru) 1972-06-16 1978-05-11
JPS5318013B2 (ru) 1973-03-19 1978-06-13
US4599430A (en) 1981-12-21 1986-07-08 The Standard Oil Company Nitrogenation of hydrocarbons, including the production of maleimide
JPS62132804A (ja) 1985-12-05 1987-06-16 Aguro Kanesho Kk 植物生長調節剤
US5412137A (en) 1993-06-07 1995-05-02 Sandoz Ltd. Process for preparing phosphinyloxy propanaminium inner salt derivatives
WO1996011908A1 (en) 1994-10-13 1996-04-25 Peptide Technology Limited Modified polyunsaturated fatty acids
US5919816A (en) 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
US5741211A (en) 1995-10-26 1998-04-21 Medtronic, Inc. System and method for continuous monitoring of diabetes-related blood constituents
GB9618420D0 (en) 1996-09-04 1996-10-16 Scotia Holdings Plc Fatty acid treatment
US6187747B1 (en) 1997-09-08 2001-02-13 Panacea Biotech Limited Pharmaceutical composition comprising cyclosporin
EP1025842B1 (en) 1997-10-30 2004-07-21 Morishita Jintan Co., Ltd. Double-leyered capsule of unsaturated fatty acid or derivative thereof and process for producing the same
WO2000009075A2 (en) 1998-08-14 2000-02-24 Galenica Pharmaceuticals, Inc. Chemically modified saponins and the use thereof as adjuvants
BR0009520A (pt) 1999-04-01 2002-06-11 Esperion Therapeutics Inc Composto, método para sintetizar o mesmo, composição, metódos para o tratramento ou prevenção, em um paciente, de doença cardiovascular, dislipidemia, dislipoproteinemia, distúrbio de metabolismo de glucose, doença de alzheimer, sìndrome x ou sìndrome metabólica, septicemia, distúrbio trombótico, distúrbio associado com receptor ativado por proliferador de peroxissoma, obesidade, pancreatite, hipertensão, doença renal, câncer, inflamação, impotência, para reduzir o teor de gordura de carne de gado bovino, e, para reduzir o teor de colesterol de ovos de aves
WO2001006983A2 (en) 1999-07-22 2001-02-01 Incell Corporation, Llc Fatty acids to minimize cancer therapy side effects
SE9903028D0 (sv) 1999-08-27 1999-08-27 Astra Ab New use
AUPQ291499A0 (en) 1999-09-17 1999-10-07 Women's And Children's Hospital Adelaide Novel nitro and sulphur containing compounds
US6346231B1 (en) 1999-10-06 2002-02-12 Joar Opheim Flavored gelatin capsule and method of manufacture
US20010037598A1 (en) 1999-12-14 2001-11-08 Suppes Galen J. Process for producing cetane improvers from triglycerides
CN1951899B (zh) 2000-02-16 2012-02-01 布里格姆及妇女医院股份有限公司 阿司匹林触发的脂质介体
AR034120A1 (es) 2000-04-13 2004-02-04 Pharmacia Corp Compuesto derivado halogenado del acido 2-amino-4,5 heptenoico, composicion farmaceutica que lo comprende y el uso de dicho compuesto y dicha composicion en la fabricacion de un medicamento para inhibir o modular la sintesis de acido nitrico
AR030416A1 (es) 2000-04-13 2003-08-20 Pharmacia Corp COMPUESTO DERIVADO HALOGENADO DEL ACIDO 2-AMINO-3,4 HEPTENOICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE Y SU USO EN LA FABRICACION DE UN MEDICAMENTO uTIL COMO INHIBIDOR DE LA OXIDO NITRICO SINTETASA
AR032318A1 (es) 2000-04-13 2003-11-05 Pharmacia Corp Compuesto derivado halogenado del acido 2-amino-5,6 heptenoico; composicion farmaceutica que lo comprende y su uso en la fabricacion de un medicamento util como inhibidor de la oxido nitrico sintetasa
EP1294658B1 (en) 2000-06-28 2005-03-02 ZAMBON GROUP S.p.A. Process for the preparation of nitroalkenes
AR031129A1 (es) 2000-09-15 2003-09-10 Pharmacia Corp Derivados de los acidos 2-amino-2-alquil-4-hexenoico y -hexinoico utiles como inhibidores de oxido nitrico sintetasa
EA007322B1 (ru) 2001-04-18 2006-08-25 Прометик Байосайенсиз, Инк. Жирные кислоты со средней длиной цепи, глицериды и аналоги как факторы, способствующие выживанию и активации нейтрофилов
US7105556B2 (en) 2001-05-30 2006-09-12 Bristol-Myers Squibb Company Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method
EP1407767A4 (en) 2001-06-18 2007-01-24 Yamada Sachiko AGONIST MEDICINAL PREPARATIONS PPAR $ G (G)
US6998395B2 (en) 2001-08-17 2006-02-14 University Of Pittsburg, Administration of estradiol metabolites for the treatment or prevention of obesity, metabolic syndrome, diabetes, and vascular and renal disorders
GB0123961D0 (en) 2001-10-05 2001-11-28 Astrazeneca Ab Process and intermediates
WO2003039533A1 (en) 2001-11-06 2003-05-15 The Brigham And Women's Hospital, Inc. Lipoxins and aspirin-triggered lipoxins and their stable analogs in the treatment of asthma and inflammatory airway diseases
US7759395B2 (en) 2002-08-12 2010-07-20 The Brigham And Women's Hospital, Inc. Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma
CA2496411A1 (en) 2002-08-20 2004-03-04 Protemix Corporation Limited Dosage forms and related therapies
BR0314799A (pt) 2002-09-27 2005-07-26 Market Biosciences Corp Controle glicêmico aperfeiçoado para pré-diabetes e/ou diabetes do tipo ii usando ácido docosahexaenóico
US7166575B2 (en) 2002-12-17 2007-01-23 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
WO2005016864A1 (en) 2003-07-29 2005-02-24 The Arizona Disease Control Research Commission Conjugated nitro alkene anticancer agents based on isoprenoid metabolism
US20050136103A1 (en) 2003-09-17 2005-06-23 Ben-Sasson Shmuel A. Compositions capable of facilitating penetration across a biological barrier
US7935365B2 (en) 2003-10-22 2011-05-03 Enzymotec, Ltd. Glycerophospholipids for the improvement of cognitive functions
US20090215895A1 (en) 2004-01-30 2009-08-27 Peplin Biolipids Pty Ltd Therapeutic and carrier molecules
AU2005329255B2 (en) 2004-04-15 2010-09-30 Chiasma, Inc. Compositions capable of facilitating penetration across a biological barrier
WO2005110396A2 (en) 2004-04-28 2005-11-24 Uab Research Foundation Nitrated lipids and methods of making and using thereof
CA2580313C (en) 2004-07-19 2016-03-15 Biocon Limited Insulin-oligomer conjugates, formulations and uses thereof
EP1772149A1 (en) 2004-07-27 2007-04-11 Kowa Company. Ltd. Drug for prevention or treatment of diabetes
CN101102988B (zh) 2004-11-19 2011-12-14 马泰克生物科学公司 来自长链多不饱和脂肪酸的氧脂素及其制备和使用方法
WO2006086727A2 (en) 2005-02-09 2006-08-17 Entelos, Inc. Treating diabetes with glucagon-like peptide-1 secretagogues
US9274129B2 (en) 2006-05-31 2016-03-01 Lpath, Inc. Methods and reagents for detecting bioactive lipids
WO2008008767A2 (en) 2006-07-14 2008-01-17 Cedars-Sinai Medical Center Methods of using ppar-gamma agonists and caspase-dependent chemotherapeutic agents for the treatment of cancer
BRPI0714562A2 (pt) 2006-07-19 2013-04-02 Resolvyx Pharmaceuticals Inc composiÇÕes e mÉtodos para o tratamento de mucosites
EP2120920A4 (en) 2007-02-20 2011-06-15 Martek Biosciences Corp OXYLIPINES OF LONG-CHAIN MULTIPLE-UNSATURATED FATTY ACIDS AND METHOD FOR THEIR PREPARATION AND USE
DK2180787T3 (da) 2007-08-01 2014-02-03 Univ Pittsburgh Nitrooliesyremodulering af type ii-diabetes
EP2207543A2 (en) 2007-09-14 2010-07-21 Resolvyx Pharmaceuticals, Inc. Omega-3 fatty acids, hydroxy polyunsaturated fatty acids, lipoxin compounds, or oxylipin compounds for treating autoimmune diseases or inhibiting immune function
CN102066924B (zh) 2008-04-18 2013-03-27 犹他大学研究基金会 使用硝化脂质治疗脂质病症和肥胖以及与脂质和肥胖相关的病状
DK2280928T3 (en) 2008-05-01 2018-11-05 Complexa Inc Vinyl-substituted fatty acids
WO2009149496A1 (en) 2008-06-10 2009-12-17 Central Northern Adelaide Health Service Treatment of diabetes and complications thereof and related disorders
US20140024713A1 (en) * 2008-06-19 2014-01-23 University Of Utah Research Foundation Use of nitrated lipids for treatment of side effects of toxic medical therapies
WO2009155439A2 (en) 2008-06-19 2009-12-23 University Of Utah Research Foundation Use of nitrated lipids for treatment of side effects of toxic medical therapies
US8518930B2 (en) 2008-07-29 2013-08-27 Nerviano Medical Sciences S.R.L. Therapeutic combination comprising a CDKS inhibitor and an antineoplastic agent
US9139554B2 (en) 2008-10-09 2015-09-22 Tekmira Pharmaceuticals Corporation Amino lipids and methods for the delivery of nucleic acids
WO2010078504A1 (en) 2008-12-31 2010-07-08 Nitromega Corp. Nutraceuticals containing nitro fatty acids
US8937194B2 (en) * 2008-12-31 2015-01-20 Nitromega Corp. Topical compositions containing nitro fatty acids
US20100286257A1 (en) 2009-05-08 2010-11-11 Perricone Nicholas V Methods Of Use Of Nitroalkane Compositions In Dermatologic Applications To Prevent or Treat Skin Aging
US20100286271A1 (en) 2009-05-08 2010-11-11 Perricone Nicholas V Nitro-alkyl Compound Compositions
US20100286272A1 (en) 2009-05-08 2010-11-11 Perricone Nicholas V Methods Of Use Of Nitroalkene Compositions In Dermatologic Applications
EP2459510A4 (en) 2009-07-29 2013-08-07 Phenomenome Discoveries Inc HYDROXIDE-FATTY ACID COMPOSITIONS AND USES THEREOF FOR ILLNESS TREATMENT AND DIAGNOSIS
CA2769624C (en) 2009-07-31 2018-09-11 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Electrophilic fatty acid derivatives as anti-inflammatory agents
EP2483233A4 (en) 2009-10-02 2013-08-14 Complexa Inc HETEROATOMA CONTAINING SUBSTITUTED FATTY ACIDS
KR20120130078A (ko) 2009-11-09 2012-11-28 메디비르 아베 신규한 1,3-옥사졸리딘 화합물 및 이의 레닌 억제제로서의 용도
WO2011098746A1 (en) 2010-02-09 2011-08-18 Pulmagen Therapeutics (Inflammation) Limited Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
RU2567049C2 (ru) * 2010-03-15 2015-10-27 Ульрих ДИТЦ Применение нитрокарбоновых кислот для лечения, диагностики и профилактики агрессивных форм заживления
US8563609B2 (en) * 2010-05-13 2013-10-22 Nitromega Corp. Nitro fatty acids - neuroprotection and/or inhibition of cognitive decline
CA2804144A1 (en) 2010-06-28 2012-01-12 Complexa, Inc. Multi-component pharmaceuticals for treating diabetes
WO2013028501A1 (en) 2011-08-19 2013-02-28 The University Of Utah Research Foundation Combination therapy with nitrated lipids and inhibitors of the renin-angiotensin-aldosterone system
US9271952B2 (en) 2011-10-11 2016-03-01 Complexa, Inc. Compositions and methods for treating nephropathy
DE102012008730A1 (de) * 2011-12-02 2013-06-06 Dr. Budz GmbH Orale Zusammensetzungen mit ungesättigten C18-Fettsäuren und ihre Verwendung
EP2809317A4 (en) 2012-02-03 2015-07-22 Univ Pittsburgh FATTY ACIDS AS ANTI-INFLAMMATORY AGENTS
US20140271844A1 (en) * 2013-03-15 2014-09-18 Nitromega Corp. Compositions containing nitro fatty acids
WO2014183108A1 (en) 2013-05-10 2014-11-13 Nitromega Corp. Nutritional or dietary supplements containing fatty acids and nitrite
US20150051283A1 (en) 2013-06-14 2015-02-19 Complexa, Inc. Composition and method for inhibition of pkng from mycobacterium tuberculosis
WO2015073527A1 (en) 2013-11-12 2015-05-21 Complexa, Inc. Nitroalkene tocopherols and analogs thereof for use in the treatment and prevention of inflammation related conditions
WO2016161285A1 (en) * 2015-04-02 2016-10-06 Aobiome Llc Production of nitro-fatty acids and nitro-hydrocarbons by ammonia oxidizing bacteria
CA3000842A1 (en) * 2015-10-02 2017-04-06 Complexa, Inc. Prevention, treatment and reversal of disease using therapeutically effective amounts of activated fatty acids

Also Published As

Publication number Publication date
US20170095437A1 (en) 2017-04-06
EP3355879A4 (en) 2019-05-22
CO2018004576A2 (es) 2018-07-19
KR20180098222A (ko) 2018-09-03
IL258476A (en) 2018-06-28
EP3355879A1 (en) 2018-08-08
CR20180246A (es) 2018-11-22
AU2021205027A1 (en) 2021-08-12
US20200046669A1 (en) 2020-02-13
CN108430466A (zh) 2018-08-21
US10537541B2 (en) 2020-01-21
JP2018529779A (ja) 2018-10-11
IL297844A (en) 2023-01-01
AU2016331314A1 (en) 2018-05-17
IL258476B (en) 2022-12-01
CN113440506A (zh) 2021-09-28
CL2018000835A1 (es) 2018-09-14
WO2017059451A1 (en) 2017-04-06
JP2021183640A (ja) 2021-12-02
IL258476B2 (en) 2023-04-01
US20220000824A1 (en) 2022-01-06
HK1259031A1 (zh) 2019-11-22
BR112018006687A2 (pt) 2018-10-09
CA3000842A1 (en) 2017-04-06
SG10201913953UA (en) 2020-03-30
MX2018004043A (es) 2018-11-09

Similar Documents

Publication Publication Date Title
EA201890859A1 (ru) Предотвращение, лечение и обращение развития заболевания с применением терапевтически эффективных количеств активированных жирных кислот
EA201792354A1 (ru) Композиции обетихолевой кислоты и способы применения
BR112018010650A8 (pt) pró-fármacos de um inibidor de jak composto para o tratamento da doença inflamatória gastrointestinal
EA201691803A1 (ru) Ингибиторы калликреина плазмы человека
MA40240A (fr) Composés hétéroaryle d'inhibition de la kinase
EA201792047A1 (ru) Новые соединения
EA201890767A1 (ru) C4-модифицированные производные олеаноловой кислоты для ингибирования il-17 и других применений
EA201790088A1 (ru) Ингибиторы syk
EA201892339A3 (ru) Несиалированный выделенный полипептид, способ получения указанного полипептида и фармацевтическая композиция для лечения воспалительного заболевания
BR112017009647A2 (pt) 2-amino-3,5-difluoro-3,6-dimetil-6-fenil-3,4,5,6-tetraidropiridinas como inibidoras da bace1 para tratar a doença de alzheimer
EA201892216A1 (ru) Замещенные производные индолина в качестве ингибиторов репликации вирусов денге
BR112018005905A2 (pt) ?composto, composição farmacêutica, métodos para evitar ou tratar uma doença ou condição, lesões de órgão, hepatotoxicidade e fígado gorduroso, e, uso de um composto?
EA201291099A1 (ru) Новые иммуномодуляторные и противовоспалительные соединения
EA201890878A1 (ru) Способ лечения медуллобластомы с помощью ингибитора ezh2
MX2017005861A (es) Metodos para el control transcripcional objetivo en regiones del super mejorador.
EA201890815A1 (ru) Аминокислотные композиции с модифицированным высвобождением для перорального введения
EA201592254A1 (ru) Производные пиразолопирролидин-4-она и их применение при лечении заболевания
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
EA201792341A1 (ru) Производные пиразола, пригодные в качестве ингибиторов белка, активирующего 5-липоксигеназу (flap)
EA202091396A1 (ru) Композиции и способы лечения метаболических состояний
EA201491500A1 (ru) Способы лечения фиброза
EA201791807A1 (ru) Новый тритерпенон по с-3 с обратными амидными производными по с-17 в качестве ингибиторов вич
CL2018001548A1 (es) Tratamiento de colestasis intrahepática y enfermedades del hígado relacionadas
EA201890862A1 (ru) Ингибиторы плазменного калликреина человека
EA201792610A1 (ru) Способ лечения неврологического заболевания